Anifrolumab for Systemic Lupus Erythematosus: A Clinical Study of Japanese Patients at Kanazawa University Hospital
November 2023
in “
The Journal of Dermatology
”
TLDR Anifrolumab effectively improved symptoms and reduced steroid use in Japanese patients with systemic lupus erythematosus.
The study conducted at Kanazawa University Hospital evaluated the effectiveness of anifrolumab in treating systemic lupus erythematosus (SLE) in seven Japanese patients, comprising one male and six females aged 31-68 years. The treatment period spanned from January 2022 to February 2023. Anifrolumab was found to be effective in reducing the SLE disease activity index-2000 (SLEDAI-2K) and cutaneous lupus erythematosus disease area and severity index (CLASI) activity scores, with a median decrease of 100%. Additionally, the treatment allowed for a reduction in oral corticosteroid dosage for all patients who continued the therapy. One patient discontinued due to uncontrolled pleurisy and pericarditis. The study concludes that anifrolumab is effective in managing SLE and reducing corticosteroid dependency.
